01—Abstract
Summary
Summary of the 8-K filed October 21, 2024. Cited figures are marked; the original filing is the authoritative source.
Medpace Holdings, Inc. (Nasdaq: MEDP) reported third quarter 2024 results on October 21, 2024, via a press release furnished as Exhibit 99.1 under Item 2.02.
Third quarter revenue rose 8.3% to $533.3 milliona from $492.5 million, while net new business awards were $533.7 million, down 12.7% from $611.5 million, giving a net book-to-bill ratio of 1.00x. Backlog increased 8.8% to $2,927.4 million as of September 30, 2024. Profitability improved substantially.
GAAP net income for the quarter was $96.4 millionb, or $3.01 per diluted share, versus $70.6 million, or $2.22 per diluted share, a year earlier. EBITDA rose 31.7% to $118.8 million, with an EBITDA margin of 22.3% compared with 18.3% in the prior-year period. For the nine months ended September 30, 2024, revenue was $1,572.5 million, up 13.3%, and GAAP net income was $287.4 million, or $8.96 per diluted share.
The company ended the quarter with $656.9 millionc in cash and cash equivalents and generated $149.1 million in operating cash flow in the third quarter. No share repurchases were made in the quarter, and $308.8 million remained under the authorized repurchase program. Full-year 2024 guidance calls for revenue of $2.090 billion to $2.130 billion, GAAP net income of $376.0 million to $388.0 million, and EBITDA of $450.0 million to $470.0 million.
02—Key points
Key Highlights
- Third quarter 2024 revenue increased 8.3% to $533.3 million; on a constant currency basis, revenue rose 8.1%.
- Net new business awards declined 12.7% to $533.7 million, yielding a net book-to-bill ratio of 1.00x.
- Backlog grew 8.8% to $2,927.4 million as of September 30, 2024.
- Q3 GAAP net income was $96.4 million, or $3.01 per diluted share, versus $2.22 per diluted share a year earlier; EBITDA rose 31.7% to $118.8 million with a 22.3% margin.
- Cash and cash equivalents totaled $656.9 million at September 30, 2024, and operating cash flow was $149.1 million in the quarter.
- No share repurchases occurred in Q3 2024; $308.8 million remained under the authorized repurchase program.
- 2024 guidance: revenue of $2.090–$2.130 billion, GAAP net income of $376.0–$388.0 million, diluted EPS of $11.71–$12.09, and EBITDA of $450.0–$470.0 million.
03—Questions
Frequently Asked Questions
How did Medpace perform in the third quarter of 2024?
Revenue grew 8.3% to $533.3 million, GAAP net income reached $96.4 million ($3.01 per diluted share), and EBITDA increased 31.7% to $118.8 million, with the EBITDA margin rising to 22.3% from 18.3%.
Was new business demand strong in the quarter?
Net new business awards were $533.7 million, a 12.7% decrease from $611.5 million a year earlier. The net book-to-bill ratio was 1.00x, meaning awards matched revenue. Backlog nonetheless increased 8.8% to $2,927.4 million.
What is the company's financial position and capital return activity?
Cash and cash equivalents were $656.9 million at September 30, 2024, up from $245.449 million at December 31, 2023. The company made no share repurchases in Q3 2024 and had $308.8 million remaining under its authorized program.
What does the company expect for full-year 2024?
Medpace forecasts 2024 revenue of $2.090 billion to $2.130 billion, GAAP net income of $376.0 million to $388.0 million, diluted EPS of $11.71 to $12.09, and EBITDA of $450.0 million to $470.0 million. Guidance assumes a tax rate of 15.5% to 16.5% and 32.1 million diluted shares.
Where can investors find more detail on these results?
The full press release is furnished as Exhibit 99.1. A conference call is scheduled for 9:00 a.m. ET on October 22, 2024, with a webcast and supplemental slide presentation available in the Investors section of the company's website.
04—Continue